| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:1935846 | IVTH | 0.00001 M | 0.00001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer |
| IVR | 1 - 50 mg | 50 mg | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0000001 M | 0.0000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.000001 M | 0.000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| IVTH | 0.00001 M | 0.00001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations | |
| PMID:34282716 | IVR | 0.1 mg/kg | 0.1 mg/kg | Induce apoptosis in liver | Hepatic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Oxidative stress in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Necrosis of liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased Aspartate aminotransferase (AST) level | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased Alkaline phosphatase (ALP) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased albumin levels in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased globulin levels in liver | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Increased Alanine aminotransferase (ALT) levels | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Changes in liver morphology | Hepatic endocrine-mediated perturbations | |
| IVR | 0.1 mg/kg | 0.1 mg/kg | Affects xenobiotic metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:34995913 | IVR | 0.5 mg/L | 0.5 mg/L | Decreased mitochondrial membrane potential in ovarian cells | Reproductive endocrine-mediated perturbations |
| IVR | 0.5 mg/L | 0.5 mg/L | Increased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/L | 0.5 mg/L | Affects ovarian follicle development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/L | 0.5 mg/L | Abnormal oocyte morphology | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.